<DOC>
	<DOCNO>NCT02119156</DOCNO>
	<brief_summary>This study assess effect 24-week withdrawal follow 28-week reintroduction belimumab 10 mg/kg plus standard care medication subject stable low systemic lupus erythematosus ( SLE ) disease activity . Rebound phenomenon assess subject permanently withdraw belimumab treatment .</brief_summary>
	<brief_title>Belimumab Treatment Holiday Treatment Re-start Study Lupus Patients .</brief_title>
	<detailed_description>This study assess effect 24-week withdrawal belimumab follow 28-week reintroduction belimumab 10 mg/kg plus standard care medication immunogenicity , marker biological activity , efficacy , safety subject stable low systemic lupus erythematosus ( SLE ) disease activity . Additionally , study ass rebound phenomenon subject disease level SLE permanently withdraw belimumab treatment</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>Received minimun 6 month therapy belimumab 10 mg/kg current SLE belimumab continuation study . Be 18 year age Day 0 visit . Nonprenant , nonlactating female willing comply specific birth control requirement set forth protocol . Able provide write informed consent participate . Subjects wish enroll control group group take 6 month belimumab treatment holiday need SELENA SLEDAI score 3 less minimum 6 month belimumab therapy , well C3 C4 complement level low limit central laboratory reference range , stable SLE treatment regimen 30 day screen period prior Day 0 . Subjects wish enroll longterm discontinuation group voluntarily withdraw continuation study . Subjects develop clinical evidence significant , unstable uncontrolled , acute chronic disease due SLE , experience adverse event ( AE ) belimumab continuation study could , opinion principle investigator , put subject undue risk . Subjects develop medical disease , laboratory abnormality , condition , opinion principle investigator , make subject unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>treatment holiday</keyword>
	<keyword>PGA</keyword>
	<keyword>belimumab</keyword>
	<keyword>Lymphostat-B</keyword>
	<keyword>rebound</keyword>
	<keyword>SELENA SLEDAI</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>immunogenicity</keyword>
</DOC>